Nanjing Leads Biolabs Announces Completion of H Share Full Circulation Program
Key Points
- Completion of H Share Full Circulation: Nanjing Leads Biolabs Co., Ltd. has completed the conversion of 44,391,598 Unlisted Shares into H Shares, which were listed on the Hong Kong Stock Exchange (HKEX) as of June 5, 2026.
- Regulatory Approvals: The process followed regulatory milestones including the CSRC Filing Notice and approval from the Hong Kong Stock Exchange.
- Significant Change to Shareholding Structure: The proportion of H Shares increased from 77.07% to 99.39% of the total issued shares, while Unlisted Shares dropped to just 0.61%.
- Potential Impact on Liquidity and Share Price: This substantial increase in free-floating H Shares could significantly improve the stock’s liquidity and may impact the share price, as it opens up more shares to the public and international investors.
- Investor Caution Advised: The company specifically advises shareholders and potential investors to exercise caution when dealing in the securities, implying that the changes may lead to price volatility.
Detailed News Article
Nanjing Leads Biolabs Co., Ltd. (Stock Code: 9887), a joint stock company established in the PRC, has announced the successful completion of its H Share Full Circulation Program. This strategic move was finalized with the conversion of 44,391,598 Unlisted Shares into H Shares, which began trading on the Hong Kong Stock Exchange at 9:00 a.m. on June 5, 2026.
Background and Timeline
The company had previously disclosed its intention to implement the H Share Full Circulation program in announcements dated December 15, 2025, May 8, 2026, and May 14, 2026. These announcements detailed the approval process with both the China Securities Regulatory Commission (CSRC) and the HKEX, culminating in the listing approval for the converted shares.
Reshaping the Shareholding Structure
Prior to completion of the program, Nanjing Leads Biolabs had 45,613,109 Unlisted Shares (22.93% of total shares) and 153,278,691 H Shares (77.07%). After the conversion, the number of Unlisted Shares dropped dramatically to 1,221,511 (0.61%), while H Shares surged to 197,670,289, representing 99.39% of the total issued shares (198,891,800 shares in total).
Implications for Investors
- This conversion marks a pivotal shift, making nearly all of the company’s shares available as H Shares on the HKEX. This is expected to enhance market liquidity, broaden the investor base, and potentially increase the company’s visibility among international investors.
- However, the large increase in tradable shares could also bring about increased price volatility in the short term, as the market digests the expanded float.
- Shareholders are explicitly advised to exercise caution in their investment decisions following this significant change.
Corporate Governance
As of the announcement date, the company’s board of directors comprises Dr. Kang Xiaoqiang (Chairman, Executive Director, and CEO), Dr. Lai Shoupeng, Mr. Zuo Honggang (Executive Directors), Mr. Zhang Yincheng, Dr. Chen Renhai, Dr. Wu Fenglan (Non-executive Directors), and Dr. Zhang Hongbing, Mr. Du Yilong, Ms. Du Jiliu (Independent Non-executive Directors).
Conclusion
Nanjing Leads Biolabs’ completion of the H Share Full Circulation is a major development, likely to impact the company’s share liquidity and trading dynamics. Investors should closely monitor the stock for potential price movements and adjust their strategies accordingly.
Disclaimer: The above article is for informational purposes only and does not constitute investment advice. Investors are urged to conduct their own research or consult a professional advisor before making investment decisions. The company has specifically advised caution regarding trading in its securities following the announcement.
南京樂普生物宣布完成H股全流通計劃
重點摘要
- H股全流通完成： 南京樂普生物股份有限公司已完成44,391,598股未上市股份轉換為H股，並於2026年6月5日早上9時在香港聯合交易所上市。
- 監管批准： 本次過程經中國證監會（CSRC）及香港聯交所批准。
- 股權結構重大變動： H股佔總股份比例由77.07%急升至99.39%，未上市股份降至僅佔0.61%。
- 對流動性及股價潛在影響： 大量H股流通預料將顯著提升股票流動性，並可能影響股價，尤其是吸引更多公眾及國際投資者關注。
- 投資者需審慎： 公司特別提醒股東及潛在投資者於證券交易時需保持審慎，意味著股價可能出現波動。
新聞詳情
南京樂普生物股份有限公司（股份代號：9887），於中國設立的股份有限公司，宣布成功完成H股全流通計劃。該計劃將44,391,598股未上市股份轉換為H股，並於2026年6月5日上午9時在香港聯交所正式掛牌交易。
背景與時間線
公司於2025年12月15日、2026年5月8日及5月14日分別公告其H股全流通計劃，並獲中國證監會及聯交所批准，最終獲准上市。
股權結構變化
計劃完成前，公司共有45,613,109股未上市股份（佔22.93%），H股為153,278,691股（佔77.07%）；計劃完成後，未上市股份僅餘1,221,511股（0.61%），H股增至197,670,289股（99.39%），總股份數為198,891,800股。
對投資者的啟示
- 本次轉換標誌公司近乎全部股份已成為H股，料將大幅提升市場流動性，擴大投資者基礎，並提升國際關注度。
- 惟因流通股份大增，短期內股價或有波動，投資者需密切留意。
- 公司明確提醒投資者審慎考慮相關變動後的投資決定。
公司管治
截至公告日，董事會成員包括：董事會主席、執行董事及首席執行官康小強博士，執行董事賴守鵬博士、左紅剛先生；非執行董事張銀成先生、陳仁海博士、吳鳳蘭博士；獨立非執行董事張紅兵博士、杜以龍先生、杜繼柳女士。
結語
南京樂普生物H股全流通完成，對公司股份流動性及交易格局構成重要影響。投資者應密切關注股價動態，審慎調整投資策略。
免責聲明： 以上內容僅供參考，並不構成任何投資建議。投資者應自行研究或諮詢專業意見，方作出投資決定。公司已特別提醒有關公告後證券交易需保持審慎。
